NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
25 trialsNCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00458796 2022-05-27
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
University of Leeds
Phase NA Terminated
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT00987636 2019-10-22
EWING2008
University Hospital Muenster
Phase 3 Completed
NCT00130494 2019-04-16
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT01205646 2019-04-12
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00265200 2018-03-05
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
University of Louisville
Phase 2 Terminated
NCT00099177 2017-08-16
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Hoffmann-La Roche
Phase 3 Terminated
NCT00099203 2017-08-16
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Hoffmann-La Roche
Phase 3 Terminated
NCT00171964 2017-06-01
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00172003 2016-11-18
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
Novartis
Phase 4 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT01067989 2015-07-08
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT01062503 2015-04-27
SubDueP
University Health Network, Toronto
Completed
NCT00301886 2013-11-13
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 3 Withdrawn
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072020 2013-08-02
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00588913 2013-07-10
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00060138 2013-05-15
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Chugai Pharmaceutical
Phase 1/2 Completed
NCT00326820 2013-03-13
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Wales Cancer Trials Unit
Phase 3 Unknown
NCT00003884 2013-02-21
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Novartis
Phase 3 Completed